8-K: Simulations Plus Reports Strong Second Quarter Fiscal 2024 Results, Maintains Full-Year Guidance

Simulations Plus announced a 16% increase in total revenue to $18.3 million and diluted earnings per share of $0.20 for the second quarter of fiscal year 2024, while reaffirming its full-year revenue and EPS guidance.

Summary

• Simulations Plus reported a 16% increase in total revenue to $18.3 million for the second quarter of fiscal year 2024, compared to $15.8 million in the same quarter of the previous year.
• Software revenue grew by 11% to $11.6 million, representing 63% of total revenue, while services revenue increased by 27% to $6.7 million, making up 37% of total revenue.
• The company's gross profit increased to $13.2 million, with a gross margin of 72%.
• Adjusted EBITDA for the quarter was $7.1 million, which is 39% of total revenue.
• Net income was $4.0 million, with diluted earnings per share (EPS) of $0.20, consistent with the previous year's EPS.
• For the first six months of fiscal year 2024, total revenue increased by 18% to $32.8 million.
• The company maintains its full-year revenue guidance of $66 to $69 million, representing a 10-15% increase, and EPS guidance of $0.66 to $0.68.
• A cash dividend of $0.06 per share was declared, payable on May 6, 2024, to shareholders of record as of April 29, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment with strong revenue growth, maintained guidance, and strategic initiatives. There are some challenges mentioned, but the overall tone is optimistic and confident.

Positives

• The company experienced strong growth in both software and services segments.
• Software revenue growth was driven by the Clinical Pharmacology & Pharmacometrics (CPP) and Cheminformatics business units.
• Services revenue growth was primarily driven by the Quantitative Systems Pharmacology (QSP) and Physiologically Based Pharmacokinetics (PBPK) business units.
• There are encouraging signs in biotech funding, particularly from companies with candidates in clinical trials.
• The company launched a corporate development initiative to focus on strategic investments and partnerships in early-stage technology companies.
• The company has a healthy pipeline and a solid balance sheet.
• The company is on track to achieve its fiscal year 2024 guidance.

Negatives

• Funding from large pharmaceutical companies continues to vary.
• The company experienced some volatility in project completion due to data delays and drug program start/stop decisions.
• There was a decrease in gross margin partially due to a shift in reporting where certain cost items are now reflected in cost of revenues for services.

Risks

• The company's ability to maintain its competitive advantages is a risk.
• Acceptance of new software and improved versions of existing software by customers is a risk.
• The general economics of the pharmaceutical industry could impact the company.
• The company's ability to finance growth is a risk.
• The company's ability to attract and retain highly qualified technical staff is a risk.
• Market conditions and macroeconomic factors could impact the company.
• Small biotech churn is a challenge.
• General market dynamics such as inflation, recession, and forex are risks.

Future Outlook

The company remains cautiously optimistic that demand for its products and services will continue to gain momentum as the funding environment improves, and they are on track to achieve their fiscal 2024 guidance.

Management Comments

• Our second quarter results reflected strong performance in both our software and services segments, said Shawn OConnor, Chief Executive Officer of Simulations Plus.
• For the balance of 2024, we remain cautiously optimistic that demand for our comprehensive suite of modeling and simulation software products and services will continue to gain momentum as the funding environment improves.
• Our strong performance in the first half of the year, combined with market improvement, puts us on track to achieve our guidance for fiscal 2024.
• We entered the third quarter with a healthy pipeline and a solid balance sheet, and we are confident that Simulations Plus is firmly positioned to advance its critical role in drug development workflow.

Industry Context

The company's performance reflects a positive trend in the biosimulation market, with increased demand for modeling and simulation software and services in the pharmaceutical industry. The company is also focusing on strategic investments in early-stage technology companies, which is a common strategy in the tech sector to drive innovation and growth.

Comparison to Industry Standards

• Simulations Plus's 16% revenue growth in Q2 is strong compared to some of its peers in the biosimulation and software space, although direct comparisons are difficult due to varying business models and reporting.
• Companies like Certara, which also provides biosimulation software and services, have seen similar growth trends, but specific numbers vary based on their reporting periods and business segments.
• The company's adjusted EBITDA margin of 39% is competitive, indicating efficient operations and profitability.
• The company's focus on strategic acquisitions and partnerships is in line with industry trends, where companies are looking to expand their offerings and gain a competitive edge.
• The company's software revenue mix of 55-60% and services revenue mix of 40-45% is a common split in the industry, where companies offer both software and consulting services.

Stakeholder Impact

• Shareholders will benefit from the declared cash dividend and the company's strong financial performance.
• Employees will benefit from the company's growth and strategic initiatives.
• Customers will benefit from the company's continued investment in research and development.
• Suppliers will benefit from the company's continued growth and demand for its products and services.
• Creditors will benefit from the company's strong financial position.

Next Steps

• The company will continue to focus on strategic investments and partnerships in early-stage technology companies.
• The company will continue to focus on delivering disciplined growth and achieving long-term returns for shareholders.
• The company will continue to monitor the funding environment and adjust its strategies accordingly.

Key Dates

Keywords

biosimulation, software, services, pharmaceutical, modeling, simulation, revenue, EBITDA, EPS, drug development, biotech, clinical trials